ArticleLung cancer management2020

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib.

Dolores Isla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.